HomeAVTX • NASDAQ
add
Avalo Therapeutics Inc
Previous close
$19.00
Year range
$3.39 - $19.41
Market cap
344.55M USD
Avg Volume
394.71K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 9.21M | 39.22% |
Net income | -30.62M | -232.94% |
Net profit margin | — | — |
Earnings per share | -2.19 | — |
EBITDA | -19.14M | -49.21% |
Effective tax rate | -0.04% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 111.62M | 36.35% |
Total assets | 125.10M | 27.06% |
Total liabilities | 33.55M | -55.69% |
Total equity | 91.55M | — |
Shares outstanding | 18.13M | — |
Price to book | 3.70 | — |
Return on assets | -38.14% | — |
Return on capital | -48.64% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -30.62M | -232.94% |
Cash from operations | -16.36M | -41.97% |
Cash from investing | -13.26M | — |
Cash from financing | 14.37M | — |
Net change in cash | -15.26M | -32.36% |
Free cash flow | -10.34M | 73.19% |
About
Founded
2011
Headquarters
Website
Employees
23
